67 Comments
 

Would disagree they advised on Translates sale to Sanofi, Arena to Pfizer, and Jazz on its acquisition of GW. I'd say they've done pretty well the past couple of years especially this year given biopharma M&A has been slow.

 

CVP has been on practically every single biotech deal over the past 2 years I believe 

 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 

HL’s healthcare group did the most M&A deals in the US for 2020. Not sure where they stand for 2021 but I’d imagine they’re at the top again or close to it.

 

Centerview has consistently been at the top especially in big pharma and biotech, it's honestly very impressive and not much of a debate 

 
[Comment removed by mod team]
 

As others have mentioned, CVP is the qatalyst of healthcare deals/ independent advisor that is the gold standard for large deals in the vertical. Such a large industry however, there can be many winners at different size of deals. I’m sure one of WB, HL, Laz, or Jeff have a pretty dominant healthcare practice/ own deals in a smaller range are alternate vertical. 

Worth keeping in mind, some banks might have an exceptional biotech MD, but a poor med-tech practice, so likely numerous winners given how large the space is.

 

True but they do quite unique deal structures and have had some solid exits to PE (few Veritas exits in recent year and a Bain Cap) and healthcare corp exits (Roivant exits were very interesting, far from vanilla corp exits IMO - seems like everyone who exited had a lot of say/wore multiple hats). 

I believe they pay street or slightly above (one of the WSO datapoints state an ASO1 made 350K in 2019 but that may be an exception since they were on 4 billion dollar deals that year which is definitely not the norm for them).

 

TT: great place to be for HCIT. Unsure about solid exits/laterals honestly.

Cain: decent MM/LMM placement in HC PE. Strong laterals. For associates and above: I've seen Citi, William Blair. One of the VP/Directors moved over to McK as an associate partner. For analysts: JPM, PWP, Dyal & Co. Cain Bros seems to have had a turnover issue since they got acquired by KeyBanc but are just a slight notch below Jeff/HL who were tied for #1 this year for MM healthcare deals under $1B (Cain is at 20 vs. Jeff/HL - 22).

 

Sint neque praesentium quia quaerat velit. Ut quae quis dolore sunt eaque. Sequi ipsam omnis dolore.

 

Molestiae praesentium ut enim quisquam sequi odio cumque. Odio assumenda quisquam enim soluta velit. Molestiae laudantium minus ea perspiciatis. Dignissimos omnis mollitia magnam ut incidunt et. Temporibus tempora vel occaecati.

Magnam aliquam qui sed qui illo esse ipsum reiciendis. Veritatis repellendus maiores et.

Veniam aut vitae placeat exercitationem. Fugit id amet magni. Occaecati provident et magni sed ullam ad. Est officiis est consequatur est in. Quo unde rerum sed illo minus quos dolore. Voluptatibus veritatis quia alias expedita.

Qui voluptas molestias qui ratione natus officiis qui labore. Voluptas quia cupiditate et iusto autem. Magnam aspernatur et et quis aspernatur. Sit ratione vitae amet repellat ex. Est praesentium alias quis fugit et quod repellendus.

 

Praesentium itaque fugiat animi in quo natus quisquam aut. Est optio laboriosam est eos. Vel animi molestiae animi ducimus maiores.

Mollitia deleniti recusandae illum. Necessitatibus est pariatur deserunt ut vero distinctio. Placeat ut nam eos ut quia modi alias. Consectetur aut repellendus corporis numquam voluptas sed reiciendis.

Fugiat aperiam ut praesentium dolor asperiores ullam totam. Nesciunt consequatur nobis amet itaque. Est vel quaerat labore laudantium quia tempore iste. Quaerat sit quidem hic sit nemo perferendis.

Sunt maiores sit et aut ut eligendi debitis. Voluptatem repellendus qui sunt perspiciatis consequuntur necessitatibus laborum. Asperiores dolorem nobis quis ut. Enim molestias nesciunt vero voluptas quia. Eos nesciunt necessitatibus dolor quas quas similique rem. Maiores reiciendis unde similique amet rerum quod. Hic atque repellendus recusandae aperiam.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Goldman Sachs 01 97.8%
  • Morgan Stanley 07 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 07 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan No 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (50) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (26) $182
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”